DAWN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Day One Biopharmaceuticals Inc (DAWN) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock has strong long-term growth potential, supported by favorable analyst ratings, acquisition rumors, and promising drug developments. Although there are short-term headwinds, the recent SwingMax signal and positive technical indicators suggest a solid entry point.
The MACD histogram is positive and expanding, indicating bullish momentum. RSI is neutral at 69.745, and moving averages are converging, suggesting potential for upward movement. The stock is trading near its R1 resistance level of 12.684, with key support at 10.285. Overall, the technical indicators suggest a bullish trend.
Acquisition rumors involving Ipsen and Jazz Pharmaceuticals have driven significant market interest and a 28% price surge.
Strong revenue growth in Q4 2025, up 83.92% YoY.
Favorable analyst outlook with price targets ranging from $22 to $30 and Outperform/Buy ratings.
Declining net income (-67.62% YoY) and EPS (-67.19% YoY) in Q4
Gross margin slightly decreased by 1.24% YoY.
No recent significant hedge fund or insider trading activity.
In Q4 2025, revenue increased by 83.92% YoY to $53.72M, indicating strong growth. However, net income dropped by 67.62% YoY to -$21.28M, and EPS fell by 67.19% YoY to -0.21. Gross margin slightly declined to 88.68%, down 1.24% YoY.
Analysts maintain a positive outlook with Buy/Outperform ratings. Wedbush raised the price target to $30, citing commercial growth and drug development progress. H.C. Wainwright and TD Cowen lowered price targets but still maintain Buy ratings, reflecting confidence in long-term potential.
